Recent Updates
Recently added Catalysts
NUVB Positive Sentiment Score: 75/100

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Key Takeaway: Nuvation Bio Inc. will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO David Hung and CFO Philippe Sauvage will participate in a fireside chat, which will be available via live webcast. The company aims to address major challenges in cancer treatment with its diverse pipeline of therapies.
Price reaction · baseline $4.69 (2026-05-26 close) · hit after-hours · 2 other NUVB headline(s) in the window, move may be shared
day 0 close · peak
+1.1%

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nuvation Bio is actively participating in a prominent healthcare conference.
  • The company is focused on significant advancements in cancer treatment.
  • Leadership presence at the event highlights the company's commitment to transparency.

Full Press Release Details

NEW YORK,May 27, 2026/PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 9:55 a.m. ET in New York, NY.
A live webcast of the fireside chat will be available on theInvestor Relationssection of the Nuvation Bio website. An archived recording will be available for 90 days following the event.
About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visitwww.nuvationbio.comor follow the company onLinkedInand X (@nuvationbioinc).

Media and Investor Contacts

Nuvation Bio Investor ContactJR DeVita[email protected]

Nuvation Bio Media ContactKaitlyn Nealy[email protected]

Frequently Asked Questions

When is Nuvation Bio's presentation at the Jefferies Conference?

Nuvation Bio will present on June 3, 2026, at 9:55 a.m. ET.

Who will represent Nuvation Bio at the conference?

CEO David Hung and CFO Philippe Sauvage will participate in the fireside chat.

How can I watch the presentation?

The presentation will be available via live webcast on Nuvation Bio's website.

What is Nuvation Bio's focus?

Nuvation Bio focuses on developing therapies for challenging cancer treatments.

Last updated: May 27, 2026